Abbott has announced it is initiating a voluntary recall of 20 lots of FreeStyle and FreeStyle Lite Blood Glucose Test Strips in the United States. These lots of test strips may produce erroneously low blood glucose results when used with both...
Abbott Diabetes Care said it issued a recall of its FreeStyle blood glucose test strips after...
Abbott today announced that its first-in-class, catheter-based MitraClip therapy has received U....
Abbott announced today it has received CE Marking in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System™. The new icon-driven system provides sleek design, visual glucose trend indicators and insulin logging – all delivered in a single device to support daily diabetes management.
Abbott announced today promising preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack.
Premier Healthcare Alliance awarded several new contracts for drug-eluting stents, traditional stents and other intervention products to 8 heavy hitters in the cardiology space. Abbott, Boston Scientific, and Medtronic all landed supplier deals for drug-eluting and traditional stents.
Abbott Receives FDA Clearance for FreeStyle Precision Pro Blood Glucose and β–Ketone Monitoring SystemJuly 29, 2013 11:09 am | by Abbott | News | Comments
Abbott has announced that it has received U.S. FDA clearance for its FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System, an advanced blood glucose monitoring system designed to address the key needs of hospital customers: high accuracy, efficient operation, dual-band wireless access to immediate test results, and helps in the reduction of the risk of test strip cross-contamination.
Abbott missed expectations with its 2nd-quarter sales but still managed to exceed earnings forecasts, sending shares up this morning on Wall Street. The Chicago-area company posted profits of $476 million, or 64¢ per share, on sales of $5.45 billion during the 3 months ended June 30, for sales growth of 2.5% but a bottom-line slide of 72.4%.
Abbott Laboratories announced Monday it would pay a combined $560 million to acquire two privately-held companies focused on coronary implants and laser-assisted eye surgery. The acquisitions of Idev Technologies and OptiMedica Corp will help the health care company expand its medical device offerings.
Abbott today announced that it has entered into an agreement to purchase IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and cardiologists. Under the terms of the agreement, Abbott will acquire all outstanding equity of IDEV Technologies for $310 million net of cash and debt.
Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the AbsorbT Bioresorbable Vascular ScaffoldJune 11, 2013 9:30 am | by The Associated Press | News | Comments
Abbott (NYSE: ABT) today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the AbsorbT Bioresorbable Vascular Scaffold (BVS) in patients with coronary artery disease (CAD), the most common form of heart disease.
A medical device industry analyst says Abbott Laboratories is unlikely to win approval anytime soon for its device used to repair heart valve problems, following a tepid endorsement by government experts. A Food and Drug Administration panel of heart experts voted 5-3 on Wednesday that the...
FDA Advisory Committee Votes Favorably on Abbott's Minimally Invasive MitraClip® Device for Patients with Significant Mitral Regurgitation Who Are Too High Risk for SurgeryMarch 20, 2013 7:44 pm | by PR Newswire | News | Comments
ABBOTT PARK, Ill., March 20, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of...
The FDA's Circulatory System Devices Panel voted today to make its recommendation regarding Abbott's (NYSE:ABT) premarket approval application for the MitraClip heart implant, agreeing unanimously that the device is safe but issuing a mixed result on the effectiveness and potential risks of the device.
Abbott's Minimally Invasive MitraClip® System for Mitral Regurgitation Demonstrates Positive Clinical and Quality-of-Life Results for Patients Too High Risk for SurgeryMarch 10, 2013 11:30 am | by PR Newswire | News | Comments
SAN FRANCISCO, March 10, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip® System for the treatment of mitral...
The FDA's Circulatory System Devices Panel will review data and make recommendations on Abbott's MitraClip aortic valve repair system. Abbott (NYSE:ABT) landed an FDA panel date to review its MitraClip aortic valve repair system, according to an FDA notice.
January has been a month of change for healthcare giant Abbott, and a senior medical devices analyst from GlobalData asserts that the company’s latest cardiac diagnostics product represents the first step in a line of new diagnostic products which will act to deliver growth over the next few years.
Abbott Board of Directors Approves Separation of AbbVie and Declares Special Dividend Distribution of AbbVie StockNovember 30, 2012 9:02 am | by Abbott | News | Comments
Abbott announced today that its board of directors has approved the separation of its research-based pharmaceuticals business, which will be known as AbbVie Inc., and declared a special dividend distribution of all of the outstanding shares of AbbVie common stock.
The world’s first drug-eluting bioabsorbable vascular scaffold has been launched and will revolutionize the stent industry. On September 25th, 2012, Abbott announced the launch of its drug-eluting bioabsorbable stent, Absorb, in Europe, the Middle East and parts of Asia Pacific and Latin America. Absorb, which received CE mark certification in 2011, is used to treat coronary artery disease.
A look at the most acquisitive medical device companies, culled from MassDevice.com's Big 100 database of more than 1,300 medical device industry transactions. More than $50 billion was spent on acquisitions by Big 100 medical device companies from the beginning of 2011 through the 1st half of 2012.